netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Insulin found 34 matches

Formulary items 22 matches
Sub Section Title / notes 6  matches
   
Open monograph to display formulary status BNF Category
  Biphasic Insulin Aspart  (NovoMix® 30)
(Analogue) 		Endocrine system - Biphasic insulins - 06.01.01.02
  Biphasic Insulin Lispro  (Humalog® Mix 25 amd Mix 50)
(Analogue) 		Endocrine system - Biphasic insulins - 06.01.01.02
  Biphasic Isophane Insulin  (Humulin® M3)
(Conventional ) 		Endocrine system - Biphasic insulins - 06.01.01.02
  Insulin  (Actrapid® )
(Rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin  (Humulin® S)
(Rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Aspart  (Fiasp®)
(Ultra-fast, short acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Aspart  (NovoRapid® Trurapi®)
(Very rapidly acting ) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin degludec  (Tresiba®)
(Long acting) 		Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Insulin Detemir  (Levemir®)
(Long acting) 		Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Insulin Glargine  (Lantus®)
(Long acting) 		Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Insulin Glargine  (Toujeo®)
(Long acting) 		Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Insulin Glargine biosimilar Abasaglar®
(Long acting) 		Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Insulin Glulisine  (Apidra®)
(Very rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Human 500 units in 1mL  (Humulin R®)
(Rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Lispro 100 units/ml  (Humalog®)
(Very rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Lispro 200 units/ml  (Humalog®)
(Very rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Insulin Lispro Sanofi
(Very rapidly acting) 		Endocrine system - Short-acting insulins - 06.01.01.01
  Isophane Insulin  (Humulin® I) Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Isophane Insulin  (Insulatard®) Endocrine system - Intermediate- and long-acting insulins - 06.01.01.02
  Anakinra  (Kineret®) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Freestyle Libre 3® Endocrine system - Blood glucose monitoring - 06.01.06
  Sotagliflozin Endocrine system - SGL2 inhibitors - 06.01.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection MHRA Drug Safety Update (Jun 2019): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued (06.01.02.03)
link in subsection MHRA Drug Safety Update (October 2024): Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme (06.01.06)
link in subsection MHRA Drug Safety Update (Sep 2020): Insulins (all types): risk of cutaneous amyloidosis at injection site (06.01.01)
link in subsection NICE TA151: Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (06.01.01)
link in drug section NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes (06.01.02.03)
link in drug section NTAG: Abasaglar® Insulin Glargine Biosimilar 100 units/ml for the treatment of type 1 or type 2 diabetes mellitus.  (06.01.01.02)

SubSection Titles / notes  
Biphasic Insulins - (06.01.01.02)
Blood glucose meters for patients on continuous Insulin infusion pump - (06.01.06)
Insulins - (06.01.01)
Intermediate- and long-acting Insulins - (06.01.01.02)
Short-acting human Insulin analogues - (06.01.01.01)
Short-acting Insulins - (06.01.01.01)

 
netFormulary